CEO & Co-Founder, Seuss+

Governance Is the Design System

Kieran Engels works with biotech sponsors to fix the part of clinical development most organizations get wrong: the governance, the oversight, and the accountability structures that sit between strategy and delivery.

Kieran Engels, CEO and Co-Founder of Seuss+
20+
Years in Clinical Development
Phase 1-3
Program Scope
Global
Europe, North America & Beyond
Independent
No CRO or Vendor Ties
Governance
Vendor Oversight & Accountability

Who Is Kieran Engels?

  • Kieran Engels is CEO and Co-Founder of Seuss+, an independent consultancy specialising in vendor governance and clinical development oversight for biotech and pharmaceutical sponsors.
  • She has 20+ years of experience across Phase 1-3 clinical programs, advising sponsors on the governance structures between strategy and vendor delivery.
  • Seuss+ operates independently with no financial ties to CROs, vendors, or service providers, giving Kieran an unbiased perspective on sponsor-side governance.
  • Kieran Engels developed the Vendor Relationship Management Methodology (VRMM), a proprietary framework for structuring accountability across clinical vendor ecosystems.
  • She is a sought-after speaker on governance failure, execution accountability, and why most clinical program breakdowns are structural, not scientific.

The Governance Gap

Why This Work Matters

The data behind the governance problem in clinical development, and why sponsors who invest in oversight outperform those who don’t.

7.9%
Approval rate for drugs entering clinical testing
Source: BIO/Biomedtracker/Amplion, 2011-2020
$600K-$8M
Cost per day of clinical trial delays
Source: Tufts CSDD, 2024
59%
Year-over-year surge in FDA warning letters (FY2025)
Source: FDA Compliance Dashboard, 2025
70%+
Of execution failures Seuss+ identifies trace to governance gaps, not vendor capability
Source: Seuss+ internal program data, 2012-2025

What Most Sponsors Optimize For vs. What Governance Requires

What Sponsors Optimize ForWhat Governance Actually Requires
Speed to first patientPace aligned with oversight capability
Vendor cost reductionVendor accountability structures
Dashboard opticsDecision-quality data at the right level
Avoiding difficult conversationsSurfacing misalignment early
Tools and platforms as solutionsTools as inputs to governance frameworks

What I See

Four patterns keep showing up

The specifics change. The patterns do not.

Perspective

Failure Isn’t Always Scientific

Most people blame science when clinical programs fail. The harder truth: many failures happen in the handoff between strategy, governance, and execution.

“Clinical development failure is rarely caused by science alone. It most often happens in the translation between intent, decisions, and execution.”
Read the full perspective

Perspective

Speed Without Control Isn’t Acceleration

Faster timelines do not automatically produce better outcomes. Speed without governance is drift with velocity.

“Speed only creates value when it is paired with control, feedback, and ownership.”
Read the full perspective

Perspective

Vendor Failure Is a Governance Symptom

When execution breaks down, the vendor gets blamed. But the root cause is almost always upstream: the governance conditions that were set before delivery began.

“What is labeled as vendor failure is most often a symptom of weak or misaligned governance.”
Read the full perspective

Perspective

Empathy Is the Glue. Accountability Is the Structure.

Most teams treat empathy and accountability as a trade-off. In practice, they are complementary. Both are required.

“Empathy without accountability is confusion dressed up as kindness. Accountability with empathy is respect.”
Read the full perspective

What I Believe

The Age of Accountability

I believe we are overdue for a different standard in clinical development. One that values clarity over activity. Governance over documentation. Ownership over shared accountability, which in practice means no one is accountable at all.

I believe that when we examine failures honestly, many of them are not scientific. They are structural. They happen between intent and execution, between what was agreed and what was delivered.

I believe vendors are not the problem. Governance is. Not because governance is overhead, but because governance is the design system that determines whether vendors succeed or fail.

I believe this work matters. Not because it is easy, but because the alternative is to keep repeating the same patterns and calling the results inevitable. They are not.

Read the full manifesto

Where I Do This Work

Kieran Engels does this work through Seuss+, the strategy and execution consultancy she co-founded in 2012. Seuss+ works with biotech and pharmaceutical sponsors to structure vendor governance, oversight, and execution across clinical development.

What Seuss+ does in practice is the operational extension of what Kieran Engels writes and speaks about: helping sponsors get the governance right before the execution starts, and staying close enough to the work to catch what the dashboards miss.

Seuss+ is independent, Amsterdam-based, and works globally. Its approach is built on the Vendor Relationship Management Methodology (VRMM), a proprietary framework for structuring, assessing, and governing sponsor-vendor relationships across the clinical development lifecycle.

Learn About Seuss+

Frequently Asked Questions

What does Kieran Engels actually do? +

Kieran Engels advises biotech and pharmaceutical sponsors on the governance structures that sit between clinical development strategy and vendor delivery. Her work is focused on identifying and fixing the points where strategy breaks down in execution.

Does Kieran Engels work for a CRO or vendor company? +

No. Kieran Engels is independent and advises sponsors without financial ties to CROs, vendors, or service providers. Her independence is central to how she operates and what she recommends.

What is Seuss+? +

Seuss+ is the consultancy Kieran Engels co-founded to do this work at scale. Seuss+ works with sponsors to apply governance frameworks, structure vendor oversight, and improve execution accountability across clinical programs.

How does vendor governance relate to clinical program timelines? +

Governance often gets positioned as overhead that slows things down. In practice, weak governance causes delays, rework, and handoff failures. Strong governance removes friction and creates the conditions for faster, more predictable delivery.

Can Kieran Engels speak at our event or contribute to our publication? +

Yes. Kieran Engels is available for keynotes, panels, podcasts, and expert commentary on vendor governance and clinical development accountability. Specific topics and availability are listed on her speaking page.